Duke Human Vaccine Institute Receives Industry Honor
DURHAM, N.C. – The Duke Human Vaccine Institute (DHVI) recently won a Vaccine Industry Excellence Award for best academic research team.
The honor, one of 13 awarded by the World Vaccine Congress during its April 2013 meeting in Washington, recognizes individuals, organizations and research teams that have made significant contributions to vaccine development over the past year.
The DHVI was cited for its work leading to new insights into HIV vaccine protection. Last year, DHVI researchers and collaborators with the National Institute of Allergy and Infectious Diseases, the U.S. Military HIV Research Program and the Thailand Ministry of Health published research that shed light on why a promising vaccine fell short of providing broad immunity. The insight will help guide future vaccine development.
In the category of best academic research team, a panel of judges comprised of biotech industry leaders evaluated programs whose research addressed:
- current unmet medical needs;
- potential geographical and market reach; novel modes of action or technologies;
- pre-clinical phases and or study results; and
- strong grant/donor support.
The DHVI was founded in 1990 to develop vaccines and therapeutics for HIV and other emerging infections that threaten global health.
A world leader in the fight against major infectious diseases, DHVI plays an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and is a pioneer in emerging infections, biodefense research and vaccine development for HIV, TB and other diseases.